US Drug Shortages In COVID-19 Era: A Domestic Problem With Domestic Solutions
Executive Summary
Rather than rail at China, senators explored causes and corrective actions for drug shortages that are closer to home.
You may also be interested in...
India Steps Up Scrutiny After Chinese API Prices, Military Tensions Rise
A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.
US FDA And Congress: Criticism Of Leadership Ramping Up, But Bipartisan Truce Holds For Now
Senate Finance Committee’s hearing on FDA’s overseas inspection program suggests that agency’s status as a rare focus for bipartisan support amid the Trump Presidency is getting more tenuous – but still holding for the time being.
Pink Sheet Podcast: FDA User Fee Bill Mark-Up, Postmarket Quality Requirements, Fewer Adcom Meetings
Pink Sheet reporter and editors discuss the first mark-up of the House FDA user fee bill, the likelihood of more postmarketing quality requirements for drug manufacturers, and the significance of the shrinking number of FDA advisory committee meetings.